{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:26:43Z","timestamp":1769581603749,"version":"3.49.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2020\/39\/D\/NZ7\/03417"],"award-info":[{"award-number":["2020\/39\/D\/NZ7\/03417"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2020\/39\/D\/NZ7\/03417"],"award-info":[{"award-number":["2020\/39\/D\/NZ7\/03417"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2020\/39\/D\/NZ7\/03417"],"award-info":[{"award-number":["2020\/39\/D\/NZ7\/03417"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2020\/39\/D\/NZ7\/03417"],"award-info":[{"award-number":["2020\/39\/D\/NZ7\/03417"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glioblastoma (GBM) is an aggressive brain tumour with limited treatment options and poor patient survival, largely due to the blood-brain barrier (BBB) restricting effective drug delivery. In this study, we focused on two small molecular weight polyfluoroalkyl phosphonates, ZOT\n                    <jats:sub>5<\/jats:sub>\n                    -1-Me and ZOT\n                    <jats:sub>5<\/jats:sub>\n                    -1-Et, designed to permeate the BBB. Comprehensive in vitro analyses using U-87 MG cells and a panel of glioma cell lines revealed that both compounds exhibit potent cytostatic and cytotoxic activities. Mechanistically, they induce reactive oxygen species (ROS) production, triggering both intrinsic and extrinsic apoptotic pathways via caspase-dependent and caspase-independent mechanisms. Additionally, ZOT\n                    <jats:sub>5<\/jats:sub>\n                    -1-Me and ZOT\n                    <jats:sub>5<\/jats:sub>\n                    -1-Et induced DNA damage, including single-strand breaks and alkali-labile sites. Notably, ZOT\n                    <jats:sub>5<\/jats:sub>\n                    -1-Me also caused significant DNA double-strand breaks and impaired DNA repair. Furthermore, both compounds exhibited antiproliferative effects by inducing cell cycle arrest in the S phase and activating p53-p21 signalling pathway. Pre-treatment with the ROS scavenger N-acetyl-L-cysteine (NAC) effectively abrogated these cytotoxic effects, underscoring the central role of oxidative stress in mediating the compounds\u2019 antitumour activity. Collectively, our findings suggest that these polyfluoroalkyl phosphonates represent promising ROS-modulating chemotherapeutic candidates with unique mechanisms of action that may complement existing GBM treatment strategies.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-22754-0","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T13:37:58Z","timestamp":1762436278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small molecular weight polyfluoroalkyl phosphonates induce ROS-mediated cytotoxicity in glioblastoma cells: a molecular mechanism study"],"prefix":"10.1038","volume":"15","author":[{"given":"Patryk","family":"Wo\u0142odkiewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Juszczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Tokarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Wo\u017aniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Tokarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"22754_CR1","doi-asserted-by":"crossref","unstructured":"Grochans S, Cybulska AM, Simi\u0144ska D, Korbecki J, Kojder K, Chlubek D et al. Epidemiology of Glioblastoma Multiforme-Literature Review. Cancers (Basel) 2022; 14(10).","DOI":"10.3390\/cancers14102412"},{"key":"22754_CR2","doi-asserted-by":"crossref","unstructured":"Brown NF, Ottaviani D, Tazare J, Gregson J, Kitchen N, Brandner S et al. Survival Outcomes and Prognostic Factors in Glioblastoma. Cancers (Basel) 2022; 14(13).","DOI":"10.3390\/cancers14133161"},{"issue":"Pt 10","key":"22754_CR3","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1093\/brain\/awm204","volume":"130","author":"D Krex","year":"2007","unstructured":"Krex, D. et al. Long-term survival with glioblastoma multiforme. Brain 130(Pt 10), 2596\u20132606 (2007).","journal-title":"Brain"},{"issue":"10","key":"22754_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl. J. Med. 352(10), 987\u2013996 (2005).","journal-title":"N Engl. J. Med."},{"key":"22754_CR5","doi-asserted-by":"crossref","unstructured":"Obrador E, Moreno-Murciano P, Oriol-Caballo M, L\u00f3pez-Blanch R, Pineda B, Guti\u00e9rrez-Arroyo JL et al. Glioblastoma Therapy: Past, Present and Future. Int J Mol Sci 2024; 25(5).","DOI":"10.3390\/ijms25052529"},{"issue":"11","key":"22754_CR6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","volume":"376","author":"JR Perry","year":"2017","unstructured":"Perry, J. R. et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl. J. Med. 376(11), 1027\u20131037 (2017).","journal-title":"N Engl. J. Med."},{"key":"22754_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.620677","volume":"7","author":"C Olivier","year":"2020","unstructured":"Olivier, C., Oliver, L., Lalier, L. & Vallette, F. M. Drug resistance in glioblastoma: The two faces of oxidative stress. Front. Mol. Biosci. 7, 620677 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"22754_CR8","doi-asserted-by":"crossref","unstructured":"Ou A, Yung WKA, Majd N. Molecular Mechanisms of Treatment Resistance in Glioblastoma. Int J Mol Sci 2020; 22(1).","DOI":"10.3390\/ijms22010351"},{"key":"22754_CR9","doi-asserted-by":"crossref","unstructured":"Lo Dico A, Salvatore D, Martelli C, Ronchi D, Diceglie C, Lucignani G et al. Intracellular Redox-Balance Involvement in Temozolomide Resistance-Related Molecular Mechanisms in Glioblastoma. Cells 2019; 8(11).","DOI":"10.3390\/cells8111315"},{"key":"22754_CR10","doi-asserted-by":"publisher","first-page":"105136","DOI":"10.1016\/j.neuint.2021.105136","volume":"149","author":"JA Campos-Sandoval","year":"2021","unstructured":"Campos-Sandoval, J. A. et al. Antioxidant responses related to temozolomide resistance in glioblastoma. Neurochem. Int. 149, 105136 (2021).","journal-title":"Neurochem. Int."},{"issue":"30","key":"22754_CR11","doi-asserted-by":"publisher","first-page":"48081","DOI":"10.18632\/oncotarget.10129","volume":"7","author":"CRR Rocha","year":"2016","unstructured":"Rocha, C. R. R., Kajitani, G. S., Quinet, A., Fortunato, R. S. & Menck, C. F. M. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. Oncotarget 7(30), 48081\u201348092 (2016).","journal-title":"Oncotarget"},{"key":"22754_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216927","volume":"592","author":"Z Ling","year":"2024","unstructured":"Ling, Z. et al. Small-molecule Molephantin induces apoptosis and mitophagy flux blockage through ROS production in glioblastoma. Cancer Lett. 592, 216927 (2024).","journal-title":"Cancer Lett."},{"key":"22754_CR13","doi-asserted-by":"crossref","unstructured":"Orlicka-P\u0142ocka M, Fedoruk-Wyszomirska A, Gurda-Wo\u017ana D, Pawelczak P, Krawczyk P, Giel-Pietraszuk M et al. Implications of Oxidative Stress in Glioblastoma Multiforme Following Treatment with Purine Derivatives. Antioxidants (Basel) 2021; 10(6).","DOI":"10.3390\/antiox10060950"},{"issue":"1","key":"22754_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13046-021-02031-4","volume":"40","author":"M Buccarelli","year":"2021","unstructured":"Buccarelli, M. et al. Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth. J. Exp. Clin. Cancer Res. 40(1), 228 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"22754_CR15","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.drudis.2019.03.008","volume":"24","author":"ED Zanders","year":"2019","unstructured":"Zanders, E. D., Svensson, F. & Bailey, D. S. Therapy for glioblastoma: Is it working?. Drug Discov Today 24(5), 1193\u20131201 (2019).","journal-title":"Drug Discov Today"},{"issue":"3","key":"22754_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s11060-011-0564-y","volume":"104","author":"MW Pitz","year":"2011","unstructured":"Pitz, M. W., Desai, A., Grossman, S. A. & Blakeley, J. O. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J. Neurooncol. 104(3), 629\u2013638 (2011).","journal-title":"J. Neurooncol."},{"key":"22754_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2022.881584","volume":"4","author":"HM Starnes","year":"2022","unstructured":"Starnes, H. M., Rock, K. D., Jackson, T. W. & Belcher, S. M. A critical review and meta-analysis of impacts of per- and polyfluorinated substances on the brain and behavior. Front. Toxicol. 4, 881584 (2022).","journal-title":"Front. Toxicol."},{"issue":"1","key":"22754_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0378-5173(98)00025-8","volume":"166","author":"G Somogyi","year":"1998","unstructured":"Somogyi, G. et al. Targeted drug delivery to the brain via phosphonate derivatives. Int. J. Pharm. 166(1), 15\u201326 (1998).","journal-title":"Int. J. Pharm."},{"issue":"26","key":"22754_CR19","doi-asserted-by":"publisher","first-page":"10933","DOI":"10.1039\/D0NJ00963F","volume":"44","author":"PM Zag\u00f3rski","year":"2020","unstructured":"Zag\u00f3rski, P. M., Tokarz, P., Gosty\u0144ski, B. & Tokarz, P. Experimental and computational studies on the formation and biological properties of the simplest polyfluoroalkyl phosphonates. New J. Chem. 44(26), 10933\u201310945 (2020).","journal-title":"New J. Chem."},{"issue":"8","key":"22754_CR20","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.3390\/cimb45080399","volume":"45","author":"M Kluska","year":"2023","unstructured":"Kluska, M., Piastowska-Ciesielska, A. W. & Tokarz, P. Cell cycle status influences resistance to apoptosis induced by oxidative stress in human breast cancer cells, which is accompanied by modulation of autophagy. Curr. Issues Mol. Biol. 45(8), 6325\u20136338 (2023).","journal-title":"Curr. Issues Mol. Biol."},{"issue":"18","key":"22754_CR21","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1021\/bi00232a015","volume":"30","author":"M Reers","year":"1991","unstructured":"Reers, M., Smith, T. W. & Chen, L. B. J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry 30(18), 4480\u20134486 (1991).","journal-title":"Biochemistry"},{"issue":"2","key":"22754_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/mutage\/10.2.85","volume":"10","author":"J Ashby","year":"1995","unstructured":"Ashby, J., Tinwell, H., Lefevre, P. A. & Browne, M. A. The single cell gel electrophoresis assay for induced DNA damage (comet assay): Measurement of tail length and moment. Mutagenesis 10(2), 85\u201390 (1995).","journal-title":"Mutagenesis"},{"issue":"13","key":"22754_CR23","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1039\/D2DT04083B","volume":"52","author":"M Juszczak","year":"2023","unstructured":"Juszczak, M. et al. Piano-stool ruthenium(II) complexes with maleimide and phosphine or phosphite ligands: Synthesis and activity against normal and cancer cells. Dalton Trans. 52(13), 4237\u20134250 (2023).","journal-title":"Dalton Trans."},{"key":"22754_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/978-1-4939-7187-9_11","volume":"1644","author":"D Firsanov","year":"2017","unstructured":"Firsanov, D. et al. Rapid detection of \u03b3-H2AX by flow cytometry in cultured mammalian cells. Methods Mol. Biol. 1644, 129\u2013138 (2017).","journal-title":"Methods Mol. Biol."},{"key":"22754_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bcp.2016.04.009","volume":"110\u2013111","author":"M Hytti","year":"2016","unstructured":"Hytti, M. et al. Inhibition of BET bromodomains alleviates inflammation in human RPE cells. Biochem. Pharmacol. 110\u2013111, 71\u201379 (2016).","journal-title":"Biochem. Pharmacol."},{"key":"22754_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248\u2013254 (1976).","journal-title":"Anal Biochem"},{"issue":"4","key":"22754_CR27","first-page":"75","volume":"28","author":"A Korzy\u0144ska","year":"2008","unstructured":"Korzy\u0144ska, A. & Zychowicz, M. A method of estimation of the cell doubling time on basis of the cell culture monitoring data. Biocybern. Biomed. Eng. 28(4), 75\u201382 (2008).","journal-title":"Biocybern. Biomed. Eng."},{"key":"22754_CR28","unstructured":"Roth V. Doubling Time Computing; 2006 [cited 2025 Apr 13]. Available from: URL: http:\/\/www.doubling-time.com\/compute.php."},{"key":"22754_CR29","unstructured":"ATCC. Cell Lines by Gene Mutation; 2022 [cited 2025 Apr 7]. Available from: URL: https:\/\/www.atcc.org\/-\/media\/resources\/brochures\/cell-lines-by-gene-mutation.pdf."},{"key":"22754_CR30","doi-asserted-by":"crossref","unstructured":"Seker-Polat F, Pinarbasi Degirmenci N, Solaroglu I, Bagci-Onder T. Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives. Cancers (Basel) 2022; 14(2).","DOI":"10.3390\/cancers14020443"},{"issue":"4","key":"22754_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1215\/15228517-2009-025","volume":"11","author":"K Ichimura","year":"2009","unstructured":"Ichimura, K. et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro. Oncol. 11(4), 341\u2013347 (2009).","journal-title":"Neuro. Oncol."},{"key":"22754_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217601","volume":"617","author":"M Rana","year":"2025","unstructured":"Rana, M., Liou, K.-C., Thakur, A., Nepali, K. & Liou, J.-P. Advancing glioblastoma therapy: Learning from the past and innovations for the future. Cancer Lett 617, 217601 (2025).","journal-title":"Cancer Lett"},{"key":"22754_CR33","doi-asserted-by":"crossref","unstructured":"Fisher JP, Adamson DC. Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines 2021; 9(3).","DOI":"10.3390\/biomedicines9030324"},{"issue":"1","key":"22754_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0305-7372(97)90019-0","volume":"23","author":"ES Newlands","year":"1997","unstructured":"Newlands, E. S., Stevens, M. F., Wedge, S. R., Wheelhouse, R. T. & Brock, C. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 23(1), 35\u201361 (1997).","journal-title":"Cancer Treat Rev."},{"issue":"11","key":"22754_CR35","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1158\/1078-0432.CCR-03-0807","volume":"10","author":"S Ostermann","year":"2004","unstructured":"Ostermann, S. et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin. Cancer Res. 10(11), 3728\u20133736 (2004).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"22754_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1023\/A:1022592913323","volume":"61","author":"M Patel","year":"2003","unstructured":"Patel, M., McCully, C., Godwin, K. & Balis, F. M. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J. Neurooncol. 61(3), 203\u2013207 (2003).","journal-title":"J. Neurooncol."},{"issue":"2","key":"22754_CR37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1468-1331.2012.03778.x","volume":"20","author":"C Chen","year":"2013","unstructured":"Chen, C., Xu, T., Lu, Y., Chen, J. & Wu, S. The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur. J. Neurol. 20(2), 223\u2013230 (2013).","journal-title":"Eur. J. Neurol."},{"issue":"12","key":"22754_CR38","doi-asserted-by":"publisher","first-page":"14324","DOI":"10.3390\/cimb46120859","volume":"46","author":"L Gaiaschi","year":"2024","unstructured":"Gaiaschi, L., Bottone, M. G. & de Luca, F. Towards effective treatment of glioblastoma: The role of combination therapies and the potential of phytotherapy and micotherapy. Curr. Issues Mol. Biol. 46(12), 14324\u201314350 (2024).","journal-title":"Curr. Issues Mol. Biol."},{"issue":"20","key":"22754_CR39","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick, W. et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl. J. Med. 377(20), 1954\u20131963 (2017).","journal-title":"N Engl. J. Med."},{"key":"22754_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1471-2407-10-30","volume":"10","author":"T Reithmeier","year":"2010","unstructured":"Reithmeier, T. et al. BCNU for recurrent glioblastoma multiforme: Efficacy, toxicity and prognostic factors. BMC Cancer 10, 30 (2010).","journal-title":"BMC Cancer"},{"key":"22754_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia, J. et al. Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 86, 102017 (2020).","journal-title":"Cancer Treat Rev."},{"key":"22754_CR42","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jconrel.2020.09.002","volume":"328","author":"GD Cha","year":"2020","unstructured":"Cha, G. D. et al. Advances in drug delivery technology for the treatment of glioblastoma multiforme. J Control Release 328, 350\u2013367 (2020).","journal-title":"J Control Release"},{"issue":"11","key":"22754_CR43","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","volume":"18","author":"LB Nabors","year":"2020","unstructured":"Nabors, L. B. et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 18(11), 1537\u20131570 (2020).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"22754_CR44","doi-asserted-by":"crossref","unstructured":"Rajaratnam V, Islam MM, Yang M, Slaby R, Ramirez HM, Mirza SP. Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. Cancers (Basel) 2020; 12(4).","DOI":"10.3390\/cancers12040937"},{"issue":"13","key":"22754_CR45","doi-asserted-by":"publisher","first-page":"8596","DOI":"10.1021\/acs.jmedchem.1c01946","volume":"65","author":"A Thakur","year":"2022","unstructured":"Thakur, A. et al. Glioblastoma: Current status, emerging targets, and recent advances. J. Med. Chem. 65(13), 8596\u20138685 (2022).","journal-title":"J. Med. Chem."},{"issue":"4","key":"22754_CR46","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","volume":"2","author":"H Pajouhesh","year":"2005","unstructured":"Pajouhesh, H. & Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2(4), 541\u2013553 (2005).","journal-title":"NeuroRx"},{"key":"22754_CR47","doi-asserted-by":"crossref","unstructured":"Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol 2009; 9 Suppl 1(Suppl 1):S3.","DOI":"10.1186\/1471-2377-9-S1-S3"},{"issue":"8","key":"22754_CR48","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen, P. Y. et al. Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22(8), 1073\u20131113 (2020).","journal-title":"Neuro Oncol"},{"issue":"3","key":"22754_CR49","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","volume":"3","author":"SY Lee","year":"2016","unstructured":"Lee, S. Y. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 3(3), 198\u2013210 (2016).","journal-title":"Genes Dis."},{"issue":"1","key":"22754_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbcan.2017.01.004","volume":"1868","author":"T Nikolova","year":"2017","unstructured":"Nikolova, T., Roos, W. P., Kr\u00e4mer, O. H., Strik, H. M. & Kaina, B. Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling. Biochim. Biophys. Acta Rev. Cancer 1868(1), 29\u201339 (2017).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"22754_CR51","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fimmu.2016.00156","volume":"7","author":"A Salazar-Ramiro","year":"2016","unstructured":"Salazar-Ramiro, A. et al. Role of redox status in development of glioblastoma. Front. Immunol. 7, 156 (2016).","journal-title":"Front. Immunol."},{"issue":"1","key":"22754_CR52","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12943-022-01668-9","volume":"21","author":"X Qi","year":"2022","unstructured":"Qi, X. et al. Antioxidants in brain tumors: Current therapeutic significance and future prospects. Mol. Cancer 21(1), 204 (2022).","journal-title":"Mol. Cancer"},{"issue":"22","key":"22754_CR53","doi-asserted-by":"publisher","first-page":"6590","DOI":"10.1158\/1078-0432.CCR-19-0594","volume":"25","author":"BG Allen","year":"2019","unstructured":"Allen, B. G. et al. First-in-human phase I clinical trial of pharmacologic ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma. Clin. Cancer Res. 25(22), 6590\u20136597 (2019).","journal-title":"Clin. Cancer Res."},{"key":"22754_CR54","unstructured":"Allen B. A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme: University of Iowa; 2024 [cited 2025 Apr 7]. Available from: URL: https:\/\/clinicaltrials.gov\/study\/NCT02344355."},{"issue":"4","key":"22754_CR55","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ccell.2017.02.018","volume":"31","author":"JD Schoenfeld","year":"2017","unstructured":"Schoenfeld, J. D. et al. O2\u22c5- and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell 31(4), 487-500.e8 (2017).","journal-title":"Cancer Cell"},{"issue":"32","key":"22754_CR56","doi-asserted-by":"publisher","first-page":"11105","DOI":"10.1073\/pnas.0804226105","volume":"105","author":"Q Chen","year":"2008","unstructured":"Chen, Q. et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl. Acad. Sci. U S A 105(32), 11105\u201311109 (2008).","journal-title":"Proc Natl. Acad. Sci. U S A"},{"issue":"1","key":"22754_CR57","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12935-021-02099-0","volume":"21","author":"A Arabzadeh","year":"2021","unstructured":"Arabzadeh, A. et al. Therapeutic potentials of resveratrol in combination with radiotherapy and chemotherapy during glioblastoma treatment: A mechanistic review. Cancer Cell Int. 21(1), 391 (2021).","journal-title":"Cancer Cell Int."},{"issue":"7","key":"22754_CR58","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/j.1755-5949.2012.00319.x","volume":"18","author":"Y Yuan","year":"2012","unstructured":"Yuan, Y., Xue, X., Guo, R.-B., Sun, X.-L. & Hu, G. Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. CNS Neurosci. Ther. 18(7), 536\u2013546 (2012).","journal-title":"CNS Neurosci. Ther."},{"issue":"4","key":"22754_CR59","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1245\/s10434-013-3380-0","volume":"21","author":"X Wang","year":"2014","unstructured":"Wang, X. et al. Gain of function of mutant TP53 in glioblastoma: Prognosis and response to temozolomide. Ann. Surg. Oncol. 21(4), 1337\u20131344 (2014).","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"22754_CR60","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","volume":"19","author":"H Ohgaki","year":"2013","unstructured":"Ohgaki, H. & Kleihues, P. The definition of primary and secondary glioblastoma. Clin. Cancer Res. 19(4), 764\u2013772 (2013).","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"22754_CR61","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro. Oncol. 23(8), 1231\u20131251 (2021).","journal-title":"Neuro. Oncol."},{"issue":"14","key":"22754_CR62","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/0008-5472.CAN-12-3342","volume":"73","author":"OD Abaan","year":"2013","unstructured":"Abaan, O. D. et al. The exomes of the NCI-60 panel: A genomic resource for cancer biology and systems pharmacology. Cancer Res. 73(14), 4372\u20134382 (2013).","journal-title":"Cancer Res."},{"issue":"11","key":"22754_CR63","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-06-0433","volume":"5","author":"ON Ikediobi","year":"2006","unstructured":"Ikediobi, O. N. et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol. Cancer Ther. 5(11), 2606\u20132612 (2006).","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"22754_CR64","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s10637-014-0084-7","volume":"32","author":"PT Grogan","year":"2014","unstructured":"Grogan, P. T., Sarkaria, J. N., Timmermann, B. N. & Cohen, M. S. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt\/mTOR pathway inhibitory modulation. Invest. New Drugs 32(4), 604\u2013617 (2014).","journal-title":"Invest. New Drugs"},{"issue":"4","key":"22754_CR65","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3892\/or.2014.3342","volume":"32","author":"H Yin","year":"2014","unstructured":"Yin, H. et al. Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT\/mTOR signaling. Oncol. Rep. 32(4), 1610\u20131616 (2014).","journal-title":"Oncol. Rep."},{"issue":"7216","key":"22754_CR66","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nature07443","volume":"455","author":"H Zheng","year":"2008","unstructured":"Zheng, H. et al. p53 and Pten control neural and glioma stem\/progenitor cell renewal and differentiation. Nature 455(7216), 1129\u20131133 (2008).","journal-title":"Nature"},{"issue":"1","key":"22754_CR67","doi-asserted-by":"publisher","first-page":"12272","DOI":"10.1038\/s41598-020-68473-6","volume":"10","author":"Y-J Lee","year":"2020","unstructured":"Lee, Y.-J. et al. Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment. Sci. Rep. 10(1), 12272 (2020).","journal-title":"Sci. Rep."},{"issue":"10","key":"22754_CR68","first-page":"3937","volume":"6","author":"H Kato","year":"2000","unstructured":"Kato, H. et al. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin. Cancer Res. 6(10), 3937\u20133943 (2000).","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"22754_CR69","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1158\/0008-5472.CAN-07-1963","volume":"68","author":"Y Li","year":"2008","unstructured":"Li, Y. et al. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res. 68(6), 1723\u20131731 (2008).","journal-title":"Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22754-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22754-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22754-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T17:02:30Z","timestamp":1769533350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22754-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22754"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22754-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the preparation of this work the author(s) used chat.gpt in order to improve language and readability. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}}],"article-number":"38896"}}